Open AccessAnti-Inflammatory Markers IL-10 and IL-35: Role in Developing Gestational Diabetes Mellitus
Author(s) -
Adele Bahar,
Ozra Akha,
Mahdi Bordbar,
Saeid Abediankenari,
Rezaali Mohammadpoor,
Zohreh Ehsani,
Zahra Kashi
Publication year - 2020
Publication title -
journal of clinical and diagnostic research
Language(s) - English
Resource type - Journals
eISSN - 2249-782X
pISSN - 0973-709X
DOI - 10.7860/jcdr/2020/44413.13883
Subject(s) - gestational diabetes , medicine , erythrocyte sedimentation rate , pregnancy , interleukin 6 , diabetes mellitus , pathogenesis , insulin resistance , endocrinology , gestation , cytokine , gastroenterology , biology , genetics
Inflammatory state is considered as the pathogenesis of Gestational Diabetes Mellitus (GDM). Cytokines can cause insulin resistance and maybe the molecular basis of inflammation in Diabetes Mellitus (DM). Aim: To assess the level of Interleukin-10 (IL-10) in addition to a new anti-inflammatory cytokine marker Interleukin-35 (IL-35) in pregnant women with and without GDM. Materials and Methods: Participants in the study included 29 pregnant women with GDM (case group) and 29 healthy pregnant women (control group). Blood levels of IL-10, IL-35, Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP) were measured in all participants. Independent t-test and Chi-square test were used for data analysis. Quantitative data between three gestational subgroups ( 32 weeks) in each GDM and control group were compared by ANOVA test. The p-value 32 weeks) (p=0.04), but this was not true in the control group. There was no significant difference between the mean level of IL-35 at different gestational ages in both GDM and control groups. Conclusion: The present study showed the decreased level of anti-inflammatory marker IL-10 in the late stage of pregnancy in diabetic women especially during the last weeks of gestation. New inflammatory marker IL-35 was not statistically significant in GDM subjects.